News

Japanese researchers wrote about a myasthenia gravis (MG) patient who showed long-term improvement in disease symptoms after he was treated with blood purification therapy. The case report, “A Case of Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated With Outpatient Periodic Weekly Blood Purification Therapy,” appeared in Internal Medicine, the journal…

Dosing has been completed in the Phase 1 clinical trial of GTP-004, a new candidate for the treatment of symptoms associated with myasthenia gravis (MG), including gastrointestinal side effects of pyridostigmine, the investigational therapy’s developer, GT Biopharma, announced. Preliminary results suggest that GTP-004 enables the safe and well-tolerated administration of…

Researchers have found that the long-term use of the immunosuppressive drug Prograf (tacrolimus) may contribute to the development of lymphoma in patients with myasthenia gravis (MG). This finding resulted from a case report published in Internal Medicine, the journal of the Japanese Society of Internal Medicine. Myasthenia gravis…

Women with a rare form of myasthenia gravis (MG) called muscle specific kinase (MuSK) MG can have healthy pregnancies without jeopardizing outcomes or increasing the risk of disease worsening, a small group study suggests. The study, “MuSK Myasthenia gravis and Pregnancy,” was published in the journal Neuromuscular Disorders.

Alexion Pharmaceuticals announced that it has received approval to market Soliris (eculizumab) in Japan as a treatment for certain adults with generalized myasthenia gravis (gMG), according to a press release. That decision, by that country’s Ministry of Health, Labor and Welfare, makes Soliris the first and only complement inhibitor…

Higher amounts of anti-acetylcholine receptor (AchR) antibodies in the blood before surgically removing the thymus could be a good predictor of outcomes for patients with myasthenia gravis, a study published in the Open Journal of Thoracic Surgery suggests. Myasthenia gravis is an autoimmune disease characterized by the uncontrolled production…

Researchers have found that patients with myasthenia gravis (MG) who are overweight or obese have a greater risk of postoperative complications after a thymectomy — the removal of the thymus. The study, “Influence of body mass index on postoperative complications after thymectomy in myasthenia gravis patients,” was published…

An investigational treatment for myasthenia gravis, ARGX-113 (efgartigimod), being developed by the Dutch pharmaceutical firm argenx, was found to be well-tolerated and effective at improving disease symptoms as early as one week after the first infusion, trial data show. The company recently revealed top-line data from its proof-of-concept Phase 2…

Researchers found that a low-dose regimen of oral corticosteroids is better than high- or intermediate-dose regimens in maintaining treatment goals for patients with myasthenia gravis (MG). The study “Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan” was published in the…

GT Biopharma has launched a proof-of-concept Phase 1 trial of its investigational therapy GTP-004 for the treatment of myasthenia gravis. The trial’s primary goal is to demonstrate the therapy improves the gastrointestinal side effects of current treatments. “I am very pleased that GT Biopharma’s first clinical trial in patients with…